PHGDH and hepatocellular carcinoma: Wei et al. found that PHGDH was a key driver of sorafenib resistance in hepatocellular carcinoma (HCC), and the synergistic effect of the PHGDH inhibitor NCT503 and sorafenib can effectively eliminate the growth of HCC in vivo44.